科兴制药(688136.SH)：眼科制剂GB10注射液获得药物临床试验批准

Core Viewpoint - Company Kexing Pharmaceutical (688136.SH) has received approval from the National Medical Products Administration (NMPA) for clinical trials of its self-developed GB10 injection, a dual-target antibody drug for ophthalmic use [1] Group 1: Clinical Trial Approval - Kexing's wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has been granted a Clinical Trial Approval Notice by the NMPA [1] - The approval allows Shenzhen Kexing to conduct clinical trials for the GB10 injection [1] Group 2: Product Details - GB10 injection is a high-concentration ophthalmic protein drug formulation targeting both VEGF and Ang-2, with a concentration of 140 mg/mL [1] - The formulation aims to reduce injection volume or increase dosage, allowing for administration every four months, which is expected to significantly enhance patient compliance [1] Group 3: Preclinical Data - Preclinical data indicates that GB10's biological activity and animal efficacy meet international competitive standards [1] - In a laser-induced monkey model of choroidal neovascularization (CNV), GB10 effectively inhibits retinal vascular neogenesis [1]